
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. has demonstrated a consistent increase in its reimbursement pipeline, growing from 1,389 units in Q4 to 1,669 units in Q3, indicating a strong demand for its myoelectric orthosis products. The company is strategically redirecting its growth towards the large Medicare market, which is projected to contribute approximately 22% of revenue in 2024, enhancing its revenue potential. Additionally, the recent positive ruling from CMS to include MyoPro under Medicare Part B benefits significantly expands Myomo's market reach and potential for revenue growth.
Bears say
Myomo Inc has revised its 2025 revenue guidance downward, projecting a range of $40 to $42 million, significantly reduced from the previous estimate of $50 to $53 million, indicating potential difficulties in reaching its financial targets. The company has also experienced a decline in its authorized insurance backlog, dropping from 272 at the end of Q4 to 208 in the most recent period, which suggests diminishing demand or issues with sales execution. Additionally, challenges in marketing and pipeline quality have negatively impacted lead generation and conversion rates, further contributing to concerns about the company's future financial performance.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares